Skip to main content

Advertisement

SpringerLink
Log in

Coronary heart disease in HIV-infected patients

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Increased risk of coronary heart disease has emerged as a long-term concern among HIV-infected patients receiving antiretroviral therapy. HIV-infected patients may have modifiable risk factors for heart disease that are associated with HIV itself, antiretroviral therapy, or factors unrelated to HIV. Dyslipidemia, insulin resistance, and diabetes mellitus are often multifactorial in origin. Patients with lipodystrophy frequently have a constellation of metabolic changes that may predispose them to accelerated atherosclerosis. There is also concern about contributions of chronic inflammation and prothrombotic tendencies in the pathogenesis of coronary heart disease in the HIV-infected population. Several epidemiological studies support an increased relative risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy. Although absolute risk appears low in the short term, patients may accrue significant risk over time. Clinicians are advised to assess coronary heart disease risk in HIV-infected patients and to intervene to reduce the impact of modifiable risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Grunfeld C, Kotler DP, Shigenaga JK, et al.: Circulating interferon-levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991, 90:154–162.

    PubMed  CAS  Google Scholar 

  2. Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003, 42:81–92.

    Article  PubMed  CAS  Google Scholar 

  3. van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and Efavirenz elicit different changes in lipid profiles in antiretroviral therapy-naive patients infected with HIV-1. Plos Med 2004, 1:19.

    Article  Google Scholar 

  4. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201.

    Article  PubMed  CAS  Google Scholar 

  5. Currier JS, Boyd F, Kawabata H, et al.: Diabetes mellitus in HIV-infected individuals [abstract]. Proceedings from the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24–28, 2002.

  6. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-F8.

    Article  PubMed  Google Scholar 

  7. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease-inhibitor therapy. J Biol Chem 2000, 275:20251–20254.

    Article  PubMed  CAS  Google Scholar 

  8. Schwarz JM, Lee GA, Park S, et al.: Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004, 18:1852–1854.

    Article  PubMed  Google Scholar 

  9. Butt AA, Fultz SL, Kwoh CK, et al.: Risk of diabetes in HIV-infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 2004, 40:115–119.

    Article  PubMed  Google Scholar 

  10. Yoon C, Gulick RM, Hoover DR, et al.: Case-control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr 2004, 37:1464–1469.

    Article  PubMed  Google Scholar 

  11. Chow DC, Souza SA, Chen R, et al.: Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003, 4:411–416.

    Article  PubMed  Google Scholar 

  12. Bergersen BM, Sandvik L, Dunlop O, et al.: Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003, 22:731–736.

    Article  PubMed  CAS  Google Scholar 

  13. Cattelan AM, Trevenzoli M, Sasset L, et al.: Indinavir and systemic hypertension. AIDS 2001, 15:805–807.

    Article  PubMed  CAS  Google Scholar 

  14. Hewitt RG, Thompson IV WM, Chu A, et al.: Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy [abstract]. Proceedings from the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Feb 4–8, 2001.

  15. de Araujo M, Seguro AC: Vasodilator agents protect against indinavir nephrotoxicity. Antivir Ther 2003, 8:295–299.

    PubMed  Google Scholar 

  16. Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130–139.

    Article  PubMed  CAS  Google Scholar 

  17. Sattler FR, Qian D, Louie S, et al.: Elevated blood pressure in subjects with lipodystrophy. AIDS 2001, 15:2001–2010.

    Article  PubMed  CAS  Google Scholar 

  18. Gazzaruso C, Bruno R, Garzaniti A, et al.: Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377–1382.

    Article  PubMed  CAS  Google Scholar 

  19. Henry K, Kitch D, Currier J, et al.: Trends in C-reactive protein levels in a cohort of HIV-1-infected persons durably suppressed on an indinavir-based regimen (ACTG 5056) [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8–11, 2004.

  20. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109(23 Suppl1):III27-III32.

    PubMed  Google Scholar 

  21. Stein JH, Klein MA, Bellehumeur JL, et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257–262.

    PubMed  CAS  Google Scholar 

  22. Dube MP, Shankar S, Vanderluitgaren JM, et al.: Effect of indinavir (IDV) monotherapy on endothelial function in men without HIV infection [abstract]. Proceedings from the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24–28, 2002.

  23. Karmochkine M, Ankri A, Calvez V, et al.: Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost 1998, 80:208–209.

    PubMed  CAS  Google Scholar 

  24. Hadigan C, Meigs JB, Rabe J, et al.: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939–943.

    Article  PubMed  CAS  Google Scholar 

  25. Koppel K, Bratt G, Schulman S, et al.: Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitorcontaining highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 29:441–449.

    PubMed  CAS  Google Scholar 

  26. Bernasconi E, Uhr M, Magenta L, et al.: Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 2001, 15:1081–1082.

    Article  PubMed  CAS  Google Scholar 

  27. Hsue PY, Giri K, Erickson S, et al.: Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004, 109:316–319.

    Article  PubMed  Google Scholar 

  28. Matetzky S, Domingo M, Kar S, et al.: Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003, 163:457–460.

    Article  PubMed  Google Scholar 

  29. Friis-Moller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993–2003. This large, prospective cohort study demonstrated an increased relative risk of myocardial infarction in association with exposure to combination antiretroviral therapy.

    Article  PubMed  Google Scholar 

  30. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702–710. This large, retrospective analysis of data from the Veterans Administration medical system found that the benefits of antiretroviral therapy on all-cause mortality were not abrogated by large, short-term increases in rates of hospitalization or death from cardiovascular or cerebrovascular causes.

    Article  PubMed  CAS  Google Scholar 

  31. Mary-Krause M, Cotte L, Simon A, et al.: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17):2479–2486.

    Article  PubMed  Google Scholar 

  32. Klein D, Hurley LB, Quesenberry CPJ, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471–477.

    PubMed  CAS  Google Scholar 

  33. Klein D, Hurley L, Quesenberry C, Sidney S: Hospitalization for coronary heart disease and myocardial infarction among Northern California men with HIV-1 infection: additional follow-up [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8–11, 2004.

  34. Currier JS, Taylor A, Boyd F, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003, 33:506–512.

    PubMed  Google Scholar 

  35. Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613–627. These guidelines provide a sound framework for assessing and managing dyslipidemia in the HIV-infected patient.

    Article  PubMed  Google Scholar 

  36. Aberg JA, Zackin RA, Evans SR, et al.: A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: final results of ACTG 5087 [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8–11, 2004.

  37. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. AIDS 2002, 16:569–577.

    Article  PubMed  CAS  Google Scholar 

  38. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al.: Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001, 45:3445–3450.

    Article  PubMed  CAS  Google Scholar 

  39. Gerber JG, Fichtenbaum CJ, Rosenkranz S, et al.: Efavirenz is a significant inducer of simvastatin and atorvastatin metabolism: results of ACTG A5108 study [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8–11, 2004.

  40. Gerber MT, Mondy KE, Yarasheski KE, et al.: Niacin in HIVinfected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004, 39:419–425.

    Article  PubMed  CAS  Google Scholar 

  41. Wohl DA, Cunningham C, Tien H-C, et al.: A randomized, open-label clinical trial of omega-3-fatty acid (fish oil) supplementation along with diet and exercise in HIVinfected patients with hypertriglyceridemia [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8–11, 2004.

  42. Fisac C, Fumero E, Crespo M, et al.: Metabolic and body composition changes in patients switching from a protease inhibitor-containing regimen to abacavir (ABC), efavirenz (EFV) or nevirapine (NVP). Twelve-month results of a randomized study (LIPNEFA) [abstract]. Proceedings from the XIV World AIDS Conference, Barcleona, Spain, July 7–12, 2002.

  43. Opravil M, Hirschel B, Lazzarin A, et al.: A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in HIV infection. J Infect Dis 2002, 185:1251–1260.

    Article  PubMed  CAS  Google Scholar 

  44. Clumeck N, Goebel F, Rozenbaum W, et al.: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001, 15:1517–1526.

    Article  PubMed  CAS  Google Scholar 

  45. Murphy R, Pokrovsky V, Rozenbaum W, et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008/044 [abstract]. Proceedings from the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 10–14, 2003.

  46. Moreno S, Domingo P, Labarga P, et al.: Dyslipidemia improvement in patients switching from d4T to tenofovir [H-855b]. Proceedings from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Sept 14–17, 2003.

  47. Lafeuillade A, Jolly P, Chadapaud S, et al.: Evolution of lipid abnormalities in patients switched from stavudine-to tenofovir-containing regimens. J Acquir Immune Defic Syndr 2003, 33:544–546.

    PubMed  CAS  Google Scholar 

  48. Glesby MJ, Aberg J, Kendall MS, et al.: Pharmacokinetic (PK) interactions between HIV protease inhibitors (PIs) and calcium channel blockers (CCBs) [abstract ]. Program and Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, Sept 30–Oct 3, 2004.

  49. Kotler DP, Muurahainen N, Grunfeld C, et al.: Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:239–252.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of International Medicine and Infectious Diseases Department of Medicine, Weill Medical College of Cornell University, 525 E. 68th St., Box 566, 10021, New York, NY, USA

    Marshall J. Glesby MD, PhD

Authors
  1. Marshall J. Glesby MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glesby, M.J. Coronary heart disease in HIV-infected patients. Curr HIV/AIDS Rep 2, 68–73 (2005). https://doi.org/10.1007/s11904-005-0021-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-005-0021-7

Keywords

Search

Navigation